Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Cerca in Study Connect
  • NCT07221877

Not Yet Recruiting

A Study to Evaluate the Effect of KarXT on Urological Safety - CN012-0068

Aggiornato: 24 ottobre, 2025   |   ClinicalTrials.gov

Stampa il riassunto

STAI PRENDENDO IN CONSIDERAZIONE QUESTA SPERIMENTAZIONE?
Stampa questa pagina e la guida alla sperimentazione da utilizzare come supporto nel colloquio con il tuo medico
Utilizza la guida alla sperimentazione per esplorare il processo di partecipazione a una sperimentazione clinica. Cerca di comprendere i fattori chiave da considerare prima di decidere e pensa alle domande da porre al team di professionisti sanitari che sono coinvolti nella conduzione dello studio.
Stampa questa pagina CN012-0068
Scarica la guida

SELEZIONI UNA LINGUA

Dettagli della sperimentazione

  • Phase 4

    Fase

  • Sesso

  • 18-65

    Fascia d'età

  • 16

    Sede/i

  • Not Yet Recruiting

Opzioni di trattamento

Bracci dello studio
TERAPIA ASSEGNATA
Experimental: KarXT
Drug: Xanomeline/trospium chloride

Principali criteri di idoneità

Inclusion Criteria - Male and Female participants (age 18 to 65 years of age, with a primary diagnosis of schizophrenia based on psychiatric evaluation (DSM-5) and confirmed by MINI (v 7.0.2). - Participants must have a PANSS total score ≤ 80 and CGI-S score ≤ 4, at screening and baseline, and a BMI ≥18 and ≤ 40 kg/m2. - Participants must be willing and able to discontinue all antipsychotic medications prior to the baseline visit and be willing and able to comply with protocol requirements. Exclusion Criteria - Participants with newly diagnosed schizophrenia, any other DSM-5 disorder diagnosed within the past 12 months, alcohol or drug use disorder within the past 12 months, history/presence of clinically significant disease or disorder that would jeopardize participant safety or validity of study results. - Participants at risk for suicidal behavior, as well as individuals who are pregnant or breastfeeding, will be excluded from the study. - Other protocol-defined Inclusion/Exclusion criteria apply

Ti consigliamo vivamente di contattare BMS per segnalare gli effetti collaterali (eventi avversi)
Qui vengono definiti gli effetti collaterali (eventi avversi) e altri eventi da segnalare
Segnala effetti collaterali (eventi avversi) o reclami sulla qualità del prodotto: informazioni mediche

Hai domande? Invia una e-mail

Hai domande?
Invia una e-mail